Kay Roumans, PhD

CONTACT

Mijke Buitinga, PhD

CONTACT

Lead Sponsor

Maastricht University Medical Center

Age

45 - 75 years

Sex

ALL

Healthy Volunteers

Yes

•Participants are able to provide signed and dated written informed consent prior to any study specific procedures
•Participants should have suitable veins for cannulation or repeated venipuncture
•Women are post-menopausal (defined as at least 1 year post cessation of menses)
•Aged ≥ 45 and ≤ 75 years
•Body mass index (BMI) 27 - 38 kg/m2
•Stable dietary habits (no weight loss or gain \>5kg in the past 3 months)
•Sedentary lifestyle (not more than 2 hours of sports per week)
•Impaired Fasting Glucose: fasting blood glucose between 6.1 and 6.9 mmol/L and 2-h plasma glucose after ingestion of 75g oral glucose load below 7.8 mmol/L Impaired Glucose Tolerance: fasting blood glucose below 6.1 mmol/L and 2-h plasma glucose after ingestion of 75g oral glucose load between 7.8 and 11.1 mmol/L

•Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator
•Previously diagnosed with type 2 diabetes
•Patients with congestive heart failure and/or severe renal (eGFR \<50mL/min) and or liver insufficiency or another condition that may interfere with outcomes measured in this study.
•Any contra-indication MRI scanning
•Alcohol consumption of \>2 servings per day for men and \>1 servings per day for woman
•Smoking in the past 6 months
•Medication use that may influence main outcome parameters, specifically the following types of medication: Type 2 diabetes medication, corticosteroids, thyroid medication.
•Participation in research or medical examination that included PET scanning in the last 3 months
•\- Any of the criteria mentioned above to define prediabetes
•Gout
•Hypersensitivity to acipimox or to any of the excipients in the tablet
•Peptic ulcer/dyspepsia
•Medication that interferes with Acipimox (statins, fibrates).